Back to top

RBC Capital Remains a Buy on Praxis Precision Medicines (PRAX)

RBC Capital analyst Leonid Timashev maintained a Buy rating on Praxis Precision Medicines yesterday and set a price target of $449.00. According to...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Praxis Precision Medicines, Inc. (PRAX)